Lowers the risk of stroke and systemic embolism. ANDA 215233, held by Alembic. Dabigatran Etexilate Mesylate.
As of Nov 16, 2026, ANDA 215233 (Dabigatran Etexilate Mesylate), held by Alembic, was first approved by FDA on Aug 12, 2024, with 0 approved supplements and 0 published complete response letters.
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated:
| Aug 12, 2024 | Original application | Approved | None posted |
| Jun 14, 2024 | Original application | Approved |
| Dabigatran Etexilate MesylateEQ 75MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 150MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 110MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters